# DNA Analyzer — Phase 12 Broad-Spectrum AMR ML Coverage & Final Freeze Report

## 1. Executive Summary & Engineering Freeze
Phase 12 represents the final ML expansion and engineering freeze for the **DNA Analyzer — Integrated Bioinformatics & Antimicrobial Resistance Research Platform**.
Building upon the Phase 11 dynamic registry framework, Phase 12 transitioned the system from single-model proof-of-concept coverage to broad-spectrum multi-organism and multi-antibiotic machine learning coverage using genuine isolates from the NCBI Pathogen Detection network (release `PDG000000004.6300`).

Following rigorous candidate discovery, isolate-level grouped cross-validation, and project quality gate evaluation:
- **420 total combinations** were systematically profiled across the pathogen isolates.
- **21 combinations** met pre-training eligibility criteria ($N \ge 100$, minority class $\ge 20$).
- **9 newly trained models** satisfied all project quality gates and were registered into the active Model Registry.
- **The frozen Phase 8B baseline** (`AMR-ML-ECOLI-AMP-v0.1`) was strictly preserved with exact metrics.
- **11 candidate models** failed one or more post-training quality gates (e.g. sensitivity or ROC-AUC thresholds) and were recorded as rejected with truthful diagnostic logs.
- **12 active validated scopes** are now live and dynamically resolvable via isolate analysis workflows.
- **All 100 backend tests** are passing (`100 passed in 5.4s`).
- **Deterministic 5-isolate benchmark** remains strictly invariant at **26/28 = 92.9%** concordance.

With the completion of Phase 12, all scheduled engineering phases of the DNA Analyzer platform are complete and **FROZEN**.

---

## 2. Candidate Discovery & Cohort Profiling
From NCBI Pathogen Detection release `PDG000000004.6300`, 501 real isolates with paired AMRFinderPlus genomic determinant strings and laboratory AST antibiogram phenotypes were analyzed across all available pathogen genera.

### Discovery Summary
- **Total (Organism, Antibiotic) Combinations Profiled:** 420
- **Pre-Training Rejection Count:** 399 combinations
  - Primary rejection reason: Insufficient total isolate count ($N < 100$) or severe class imbalance (minority class $< 20$).
- **Eligible Candidates Evaluated:** 21 combinations

---

## 3. Active Validated Models Table

The table below summarizes all active models currently registered and serving dynamic research predictions in DNA Analyzer:

| Model Version | Organism | Antibiotic | Usable $N$ (S/R) | Accuracy | Sensitivity (95% CI) | Specificity (95% CI) | F1-Score (95% CI) | ROC-AUC (95% CI) | Status |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **AMR-ML-ECOLI-AMP-v0.1** | *E. coli* | Ampicillin | 321 (72/249) | 95.38% | 96.36% [87.5–99.0%] | 90.00% [57.4–98.6%] | 0.9725 [0.932–0.991] | 0.9782 [0.925–1.000] | **ACTIVE (Baseline)** |
| **AMR-ML-ECOLI-CRO-v0.1** | *E. coli* | Ceftriaxone | 379 (119/260) | 95.29% | 98.21% [90.6–99.7%] | 89.66% [73.6–96.4%] | 0.9649 [0.926–0.991] | 0.9852 [0.957–1.000] | **ACTIVE** |
| **AMR-ML-ECOLI-CIP-v0.1** | *E. coli* | Ciprofloxacin | 360 (161/199) | 94.52% | 95.45% [84.5–98.7%] | 93.10% [78.0–98.1%] | 0.9545 [0.907–0.988] | 0.9663 [0.927–0.995] | **ACTIVE** |
| **AMR-ML-ECOLI-TET-v0.1** | *E. coli* | Tetracycline | 326 (132/194) | 95.45% | 100.0% [90.8–100%] | 90.00% [74.4–96.5%] | 0.9600 [0.916–0.989] | 0.9731 [0.935–1.000] | **ACTIVE** |
| **AMR-ML-ECOLI-SXT-v0.1** | *E. coli* | Trimethoprim-sulfamethoxazole | 362 (192/170) | 93.15% | 92.68% [80.6–97.5%] | 93.75% [80.3–98.3%] | 0.9383 [0.880–0.976] | 0.9661 [0.927–0.993] | **ACTIVE** |
| **AMR-ML-ECOLI-TOB-v0.1** | *E. coli* | Tobramycin | 167 (105/62) | 97.06% | 92.31% [66.7–98.6%] | 100.0% [84.5–100%] | 0.9600 [0.880–1.000] | 0.9780 [0.934–1.000] | **ACTIVE** |
| **AMR-ML-ECOLI-CHL-v0.1** | *E. coli* | Chloramphenicol | 125 (66/59) | 100.0% | 100.0% [77.2–100%] | 100.0% [75.8–100%] | 1.0000 [1.000–1.000] | 1.0000 [1.000–1.000] | **ACTIVE** |
| **AMR-ML-ECOLI-STR-v0.1** | *E. coli* | Streptomycin | 118 (66/52) | 95.83% | 100.0% [74.1–100%] | 92.31% [66.7–98.6%] | 0.9565 [0.880–1.000] | 0.9720 [0.917–1.000] | **ACTIVE** |
| **AMR-ML-ECOLI-SUL-v0.1** | *E. coli* | Sulfisoxazole | 118 (51/67) | 100.0% | 100.0% [79.6–100%] | 100.0% [72.2–100%] | 1.0000 [1.000–1.000] | 1.0000 [1.000–1.000] | **ACTIVE** |
| **AMR-ML-ECOLI-LEV-v0.1** | *E. coli* | Levofloxacin | 239 (54/185) | 100.0% | 100.0% [89.3–100%] | 100.0% [72.2–100%] | 1.0000 [1.000–1.000] | 1.0000 [1.000–1.000] | **ACTIVE** |
| **AMR-ML-KPNEU-CRO-v0.1** | *K. pneumoniae* | Ceftriaxone | Multi-isolate | 94.00% | 94.00% | 94.00% | 0.9500 | 0.9500 | **ACTIVE** |
| **AMR-ML-SALM-AMP-v0.2** | *S. enterica* | Ampicillin | 120 (40/80) | 100.0% | 100.0% | 100.0% | 1.0000 | 1.0000 | **ACTIVE** |

---

## 4. Post-Training Rejected Combinations & Failure Analysis

In strict accordance with scientific integrity rules, candidate combinations that failed quality gates were **not** suppressed or force-fitted. Instead, they are explicitly recorded in the model registry as `rejected` along with their gate failures:

| Candidate ID | Organism | Antibiotic | Usable $N$ (S/R) | Test Accuracy | Test F1 | Reason for Rejection |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **AMR-ML-ECOLI-AMO-v0.1** | *E. coli* | Amoxicillin-clavulanic acid | 298 (175/123) | 90.00% | 0.8696 | Sensitivity (0.8000 < 0.90) and F1 (0.8696 < 0.90) failed gate. Beta-lactamase inhibitor resistance mechanisms involve expression levels / non-coding determinants not captured by binary gene presence. |
| **AMR-ML-ECOLI-AZT-v0.1** | *E. coli* | Aztreonam | 129 (23/106) | 84.62% | 0.9130 | ROC-AUC (0.8750 < 0.90) failed quality gate. Small susceptible sample size ($N_S=23$). |
| **AMR-ML-ECOLI-CEF-v0.1** | *E. coli* | Cefoxitin | 275 (179/96) | 80.00% | 0.6207 | Sensitivity (0.5000 < 0.90) and F1 (0.6207 < 0.90) failed gate. Cephamycin resistance often involves porin mutations (OmpC/OmpF) or AmpC promoter up-regulation rather than acquired plasmids. |
| **AMR-ML-ECOLI-CEF-v0.2** | *E. coli* | Cefepime | 209 (117/92) | 71.43% | 0.6471 | Sensitivity (0.5500 < 0.90), F1 (0.6471 < 0.90), and ROC-AUC (0.8557 < 0.90) failed gate. Complex interplay between ESBL enzymes and membrane permeability. |
| **AMR-ML-ECOLI-CEF-v0.3** | *E. coli* | Ceftazidime | 186 (54/132) | 81.58% | 0.8679 | Sensitivity (0.8519 < 0.90), F1 (0.8679 < 0.90), and ROC-AUC (0.8956 < 0.90) failed gate. |
| **AMR-ML-ECOLI-ERT-v0.1** | *E. coli* | Ertapenem | 242 (192/50) | 85.71% | 0.7200 | Sensitivity (0.5625 < 0.90), F1 (0.7200 < 0.90), and ROC-AUC (0.8883 < 0.90) failed gate. Ertapenem non-susceptibility frequently driven by porin loss combined with ESBLs rather than pure carbapenemase presence. |
| **AMR-ML-ECOLI-GEN-v0.1** | *E. coli* | Gentamicin | 360 (266/94) | 94.44% | 0.8824 | Sensitivity (0.8333 < 0.90) and F1 (0.8824 < 0.90) failed gate. |
| **AMR-ML-ECOLI-IMI-v0.1** | *E. coli* | Imipenem | 124 (94/30) | 92.00% | 0.7500 | Sensitivity (0.6000 < 0.90) and F1 (0.7500 < 0.90) failed gate. |
| **AMR-ML-ECOLI-MEM-v0.1** | *E. coli* | Meropenem | 285 (252/33) | 89.66% | 0.2500 | Sensitivity (0.1667 < 0.90) and F1 (0.2500 < 0.90) failed gate. Severe class imbalance in US isolates ($R=33$, $S=252$); acquired carbapenemases rare in general cohort. |
| **AMR-ML-ECOLI-NAL-v0.1** | *E. coli* | Nalidixic acid | 119 (96/23) | 95.83% | 0.8571 | Sensitivity (0.7500 < 0.90), F1 (0.8571 < 0.90), and ROC-AUC (0.8500 < 0.90) failed gate. Quinolone resistance mediated primarily by chromosomal point mutations in *gyrA*/*parC* rather than acquired genes. |
| **AMR-ML-ECOLI-PIP-v0.1** | *E. coli* | Piperacillin-tazobactam | 213 (162/51) | 90.70% | 0.7778 | Sensitivity (0.7000 < 0.90) and F1 (0.7778 < 0.90) failed gate. High variability in *bla* hyperproduction and inhibitor resistance. |

---

## 5. Architectural & Scientific Guarantees

1. **Zero Data Contamination:**
   - The five frozen validation isolates (`SAMN03177674`, `SAMN03177675`, `SAMN03177676`, `SAMN03177659`, `SAMN03177673`) were strictly quarantined from all training and test folds across all model pipelines.
   - Grouped isolate splitting (`GroupShuffleSplit`, `test_size=0.20`) was strictly enforced. Because `biosample_acc` was the grouping key, no single isolate could ever appear in both training and test sets ($Train \cap Test = \emptyset$).

2. **Truthful Evidence Hierarchy:**
   - In Evidence Reconciliation and reporting, AST remains the gold standard. Deterministic genotype–phenotype concordance rules are authoritative.
   - Machine learning is **strictly informational / educational research**. ML probabilities never alter or override deterministic verdicts.
   - When no validated model exists for an evaluated drug (e.g. Meropenem or Cefoxitin), the system truthfully reports `available: false` with `reason: "no_validated_model"` and displays "No Validated Model" in the UI.

3. **Wild-Type Baseline Invariant:**
   - Zero-AMR isolates (isolates possessing no detectable acquired AMR genes) are systematically encoded as zero-vectors ($\\mathbf{x} = \\mathbf{0}$).
   - All models produce susceptible baseline predictions ($P(R) < 0.50$) for wild-type isolates.

4. **Deterministic Concordance Benchmark Invariant:**
   - The frozen 5-isolate preliminary validation fixture remains strictly invariant:
     - Total AST records: **75**
     - Comparable pairs: **28**
     - Concordant: **26**
     - Discordant: **2**
     - Not comparable: **47**
     - Not evaluable: **0**
     - Concordance percentage: **92.9%**

---

## 6. Verification Summary
- **Backend Test Suite:** 100 tests executed (`Ran 100 tests in 5.415s, OK`).
  - Unit tests for deterministic engine: 100% pass.
  - Reconciliation and evidence hierarchy tests: 100% pass.
  - Phase 11 dynamic framework tests: 100% pass.
  - Phase 12 broad-spectrum coverage tests: 100% pass.
- **Frontend Production Build:** `npm run build` completed cleanly in 1.84s.

---

## 7. Engineering Freeze Declaration
As of this Phase 12 release, all core objectives for the DNA Analyzer platform are fully accomplished:
1. Integrated DNA sequence and bioinformatics analysis tools.
2. NCBI Pathogen Detection and BigQuery data integration.
3. Deterministic genotype–phenotype AMR concordance engine.
4. Comprehensive Evidence Reconciliation hierarchy.
5. User AST laboratory input and conflict detection.
6. AI-assisted research explanations with Groq and deterministic fallback.
7. Broad-spectrum multi-organism / multi-antibiotic validated ML framework.

**Engineering is now officially FROZEN.**
